



(19)

Generated Document.

(11) Publication number: **11158068 A****PATENT ABSTRACTS OF JAPAN**(21) Application number: **09363359**(51) Int. Cl.: **A61K 31/415 A61K 31/415 A61K 31/415  
A61K 31/415 A61K 31/415 A61K 31/415  
A61K 31/415**(22) Application date: **25.11.97**

(30) Priority:

(43) Date of application publication: **15.06.99**

(84) Designated contracting states:

(71) Applicant: <b>KISSEI PHARMACEUT CO LTD</b>
(72) Inventor: <b>HARADA HIROSHI TAKEHANA YASUO NONAKA YOSHISA YAZAKI TOSHIKAZU KAMATA KOJI FUSHIMI NOBUHIKO</b>
(74) Representative:

**(54) VASCULARIZATION  
INHIBITOR**


(57) Abstract:

**PROBLEM TO BE SOLVED:** To obtain the subject inhibitor which represses the multiplication and adhesion of human capillary endothelial cells and inhibits the formation of canals by including


specific 2-substituted  
carbamoylimidazol derivative as an  
active ingredient.

**SOLUTION:** This inhibitor includes  
a 2-substituted carbamoylimidazol  
derivative [e.g. ethyl (E)-2-(2-  
dimethylaminoethyl)carbamoyl)-5(4)-  
3,4,5- trimethoxycinnamoyl)amino)  
imidazol-4(5)-carboxylate or the like]  
of formula I [either A or B is a group  
of formula II (R1 is H or the like; R2  
and R3 are each H, a halogen or the  
like) and the other is a lower  
alkoxycarbonyl; R4 is a (substituted)  
alkyl or the like; R5 is H or the like]  
or its salt as an active ingredient. It is  
preferable that the above-stated  
ingredient is administered at a daily  
dosage of 0.1-1000 mg per an adult  
when used orally or 0.01-300 mg  
when used parenterally.

COPYRIGHT: (C)1999, JPO



I



II